Alveolus Bio is developing FDA-approved therapeutics that utilize advanced drug formulation techniques to enhance the delivery and efficacy of treatments for chronic respiratory illnesses. The company targets unmet medical needs in conditions such as asthma and chronic obstructive pulmonary disease (COPD) to improve patient outcomes.
Funding
Funding not disclosed
IAFounders
Product
Problem
Chronic respiratory illnesses like asthma, COPD, and Idiopathic Pulmonary Fibrosis (IPF) often require enhanced drug delivery methods to effectively target affected areas of the lungs and improve patient outcomes. Current treatments may not adequately address fibroblast dysfunction and neutrophilic inflammation associated with these conditions.
Solution
Alveolus Bio is developing inhaled biotherapeutics utilizing its proprietary resMIT platform to deliver targeted treatments directly to the lungs. This approach aims to disrupt the standard of care for chronic and infectious lung diseases by addressing fibroblast dysfunction in IPF and neutrophilic inflammation in conditions like non-cystic fibrosis bronchiectasis (NCFBE) and COPD. The company's first-in-class therapeutics are designed to enhance the efficacy of treatments while ensuring patient safety.
Target Audience
The primary target audience includes patients suffering from chronic respiratory illnesses such as asthma, COPD, and IPF, as well as the physicians and healthcare providers who treat these conditions.
Features
- Proprietary resMIT platform for targeted delivery of therapeutics to the lungs
- Focus on addressing fibroblast dysfunction in Idiopathic Pulmonary Fibrosis (IPF)
- Development of treatments for neutrophilic inflammation indications (NCFBE, COPD)
- Inhaled biotherapeutics designed for enhanced efficacy and safety